SAGE Therapeutics Inc
NASDAQ:SAGE

Watchlist Manager
SAGE Therapeutics Inc Logo
SAGE Therapeutics Inc
NASDAQ:SAGE
Watchlist
Price: 6.53 USD 0.77% Market Closed
Market Cap: 408.9m USD

Intrinsic Value

SAGE's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one SAGE stock under the Base Case scenario is 18.65 USD. Compared to the current market price of 6.53 USD, SAGE Therapeutics Inc is Undervalued by 65%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SAGE Intrinsic Value
18.65 USD
Undervaluation 65%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
SAGE Therapeutics Inc

Valuation History Unavailable

Historical valuation for SAGE cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about SAGE Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
SAGE Therapeutics Inc

Current Assets 454.5m
Cash & Short-Term Investments 423.9m
Receivables 13.4m
Other Current Assets 17.2m
Non-Current Assets 15.2m
PP&E 11.1m
Other Non-Current Assets 4.1m
Efficiency

Free Cash Flow Analysis
SAGE Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
SAGE Therapeutics Inc

Revenue
47.4m USD
Cost of Revenue
-8.8m USD
Gross Profit
38.6m USD
Operating Expenses
-398.4m USD
Operating Income
-359.8m USD
Other Expenses
5.4m USD
Net Income
-354.4m USD
Fundamental Scores

SAGE Profitability Score
Profitability Due Diligence

SAGE Therapeutics Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional Revenue Growth Forecast
Negative 1-Year Revenue Growth
26/100
Profitability
Score

SAGE Therapeutics Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.

SAGE Solvency Score
Solvency Due Diligence

SAGE Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

SAGE Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SAGE Price Targets Summary
SAGE Therapeutics Inc

Wall Street analysts forecast SAGE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SAGE is 8.21 USD with a low forecast of 5.05 USD and a high forecast of 12.6 USD.

Lowest
Price Target
5.05 USD
23% Downside
Average
Price Target
8.21 USD
26% Upside
Highest
Price Target
12.6 USD
93% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

SAGE Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for SAGE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

SAGE Insider Trading
Buy and sell transactions by insiders

SAGE News

Other Videos
What is the Intrinsic Value of one SAGE stock?

The intrinsic value of one SAGE stock under the Base Case scenario is 18.65 USD.

Is SAGE stock undervalued or overvalued?

Compared to the current market price of 6.53 USD, SAGE Therapeutics Inc is Undervalued by 65%.

Back to Top